2026 Q1 -tulosraportti
92 päivää sitten
‧34 min
25,063 SEK/osake
Viimeisin osinko
0,00%Tuotto/v
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
2025 Q4 -tulosraportti 4.2. | ||
2025 Q3 -tulosraportti 24.10.2025 | ||
2025 Q2 -tulosraportti 29.7.2025 | ||
2025 Q1 -tulosraportti 7.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·15.7.Worst in class!
Tobii has advanced strongly FUNDAMENTALLY speaking (but is robot-shorted by likely Smart Eye-associated foreign algorithm traders, as was the former subsidiary Dynavox) since the peak price of 7 kr at the end of July 2025 after the Q1 report race + good news from a price of approx. 2 kr at the beginning of May 2025. So I anticipate a new Tobii race to speculate on first, and then one can increase, for example, in Dicot Pharma in my case, perhaps with the shares instead, so that both are held, or that Tobii profit is partly transferred to a partial subscription of shares via TO-7 or similar combinations. Acquisition/agreement before a completed Phase IIb in Dicot Pharma feels quite likely - but that also depends on the price THEN, as it might eventually be cheaper with Phase III in-house, though that's a fine detail. I hope they sell the drug candidate in that case to the highest bidder... Tobii, I hope they DO NOT sell, at least in the first stage, and in fact a good bid from Dynavox of, say, 7-10 kr is OK - EVEN for Dynavox owners, assuming only new shares in Dynavox as payment. With Dynavox target prices now approx. 100 kr or more among all major banks etc., a Tobii acquisition from THEM is OK, BUT NOT if, for example, close partner Qualcomm makes a bid that could pay like 50-100 kr now :-) Or Qualcomm's competitor Texas Instrument, with whom Tobii Autosense ALSO has SCDO collaboration for generation 4 DMS at BMW, i.e., generation 3 OMS worldwide, where Autosense was first with OMS already in 2021 in BMW with Seeing Machines as a DMS supplier, while Smart Eye came up empty and completely lost BMW except in the phasing out of gen 1, which is still ongoing with one model, at least in Q1 according to Martin Krantz at Smart Eye, who has been reported by me to the EBM for other matters, i.e., insider trading and fraud regarding the concealment of BMW's DMS and OMS losses.- 3.7.Regarding Autism Tobii secures design win for Get Set Early - delivers eyetracking for autism diagnostics 2026-02-11 The eyetracking-based screening tool for Autism Spectrum Disorder aims to enable earlier diagnosis and treatment through scientifically designed tests. Tobii, the global leader in eyetracking and pioneer in attention computing, has secured a design win for Get Set Early – a screening tool for Autism Spectrum Disorder (ASD) developed to identify early signs of autism in children as young as 12 months. The screening tool was developed by psychology professor Dr. Karen Pierce and her team at the University of California San Diego, and further developed by Butterfly Learnings. It is the first tool of its kind in India to have received CDSO certification and been approved for clinical use. Early detection crucial for effective treatment Research shows that children diagnosed with autism before the age of two exhibit better linguistic, cognitive, and social development. The brain is most malleable during the first years of life, making early detection crucial for effective treatment. Get Set Early enables early identification through a non-invasive test where the child watches a short video while the system records eye movements to measure how long the child focuses on different types of stimuli. The test generates objective biomarkers for autism spectrum disorder, making the assessment reliable and unbiased. The method is patented, scientifically validated, and based on the analysis of eye movements to detect signs of autism in children. It was developed by Dr. Karen Pierce, Associate Director of the Autism Center of Excellence at the University of California, San Diego. "Through the collaboration with Tobii, we can offer high-quality eyetracking diagnostics for early autism screening in India and global markets. This is an important step forward in our mission to make high-quality, technology-driven screening accessible to all children, everywhere. We look forward to scaling this partnership globally," says Abhishek Sen, co-founder and CEO of Butterfly Learnings. Eyetracking enabled by Tobii Eye Tracker 5L Tobii provides Butterfly Learnings with Tobii Eye Tracker 5L for integration into the Get Set Early screening tool. Tobii Eye Tracker 5L is a high-performance eyetracker developed for easy integration into digital health platforms, diagnostic tools, and other cognitive assessment products. "It is an honor for Tobii to be part of a product that can truly make a difference in people's lives. We are deeply impressed by what Butterfly Learnings has achieved with Get Set Early, where fundamental research insights have been transformed into clinical use that is approved, accessible, and scalable," says Emma Bauer, Senior Vice President, Integrations, at Tobii. The Get Set Early screening tool is now being implemented in clinics across India. In the development and integration of Tobii's eyetracking technology into the tool, Butterfly Learnings and Tobii have collaborated with Tiden Technologies, Tobii's Indian reseller specializing in research-grade neuroscience technology.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
92 päivää sitten
‧34 min
25,063 SEK/osake
Viimeisin osinko
0,00%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·15.7.Worst in class!Tobii has advanced strongly FUNDAMENTALLY speaking (but is robot-shorted by likely Smart Eye-associated foreign algorithm traders, as was the former subsidiary Dynavox) since the peak price of 7 kr at the end of July 2025 after the Q1 report race + good news from a price of approx. 2 kr at the beginning of May 2025. So I anticipate a new Tobii race to speculate on first, and then one can increase, for example, in Dicot Pharma in my case, perhaps with the shares instead, so that both are held, or that Tobii profit is partly transferred to a partial subscription of shares via TO-7 or similar combinations. Acquisition/agreement before a completed Phase IIb in Dicot Pharma feels quite likely - but that also depends on the price THEN, as it might eventually be cheaper with Phase III in-house, though that's a fine detail. I hope they sell the drug candidate in that case to the highest bidder... Tobii, I hope they DO NOT sell, at least in the first stage, and in fact a good bid from Dynavox of, say, 7-10 kr is OK - EVEN for Dynavox owners, assuming only new shares in Dynavox as payment. With Dynavox target prices now approx. 100 kr or more among all major banks etc., a Tobii acquisition from THEM is OK, BUT NOT if, for example, close partner Qualcomm makes a bid that could pay like 50-100 kr now :-) Or Qualcomm's competitor Texas Instrument, with whom Tobii Autosense ALSO has SCDO collaboration for generation 4 DMS at BMW, i.e., generation 3 OMS worldwide, where Autosense was first with OMS already in 2021 in BMW with Seeing Machines as a DMS supplier, while Smart Eye came up empty and completely lost BMW except in the phasing out of gen 1, which is still ongoing with one model, at least in Q1 according to Martin Krantz at Smart Eye, who has been reported by me to the EBM for other matters, i.e., insider trading and fraud regarding the concealment of BMW's DMS and OMS losses.
- 3.7.Regarding Autism Tobii secures design win for Get Set Early - delivers eyetracking for autism diagnostics 2026-02-11 The eyetracking-based screening tool for Autism Spectrum Disorder aims to enable earlier diagnosis and treatment through scientifically designed tests. Tobii, the global leader in eyetracking and pioneer in attention computing, has secured a design win for Get Set Early – a screening tool for Autism Spectrum Disorder (ASD) developed to identify early signs of autism in children as young as 12 months. The screening tool was developed by psychology professor Dr. Karen Pierce and her team at the University of California San Diego, and further developed by Butterfly Learnings. It is the first tool of its kind in India to have received CDSO certification and been approved for clinical use. Early detection crucial for effective treatment Research shows that children diagnosed with autism before the age of two exhibit better linguistic, cognitive, and social development. The brain is most malleable during the first years of life, making early detection crucial for effective treatment. Get Set Early enables early identification through a non-invasive test where the child watches a short video while the system records eye movements to measure how long the child focuses on different types of stimuli. The test generates objective biomarkers for autism spectrum disorder, making the assessment reliable and unbiased. The method is patented, scientifically validated, and based on the analysis of eye movements to detect signs of autism in children. It was developed by Dr. Karen Pierce, Associate Director of the Autism Center of Excellence at the University of California, San Diego. "Through the collaboration with Tobii, we can offer high-quality eyetracking diagnostics for early autism screening in India and global markets. This is an important step forward in our mission to make high-quality, technology-driven screening accessible to all children, everywhere. We look forward to scaling this partnership globally," says Abhishek Sen, co-founder and CEO of Butterfly Learnings. Eyetracking enabled by Tobii Eye Tracker 5L Tobii provides Butterfly Learnings with Tobii Eye Tracker 5L for integration into the Get Set Early screening tool. Tobii Eye Tracker 5L is a high-performance eyetracker developed for easy integration into digital health platforms, diagnostic tools, and other cognitive assessment products. "It is an honor for Tobii to be part of a product that can truly make a difference in people's lives. We are deeply impressed by what Butterfly Learnings has achieved with Get Set Early, where fundamental research insights have been transformed into clinical use that is approved, accessible, and scalable," says Emma Bauer, Senior Vice President, Integrations, at Tobii. The Get Set Early screening tool is now being implemented in clinics across India. In the development and integration of Tobii's eyetracking technology into the tool, Butterfly Learnings and Tobii have collaborated with Tiden Technologies, Tobii's Indian reseller specializing in research-grade neuroscience technology.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
2025 Q4 -tulosraportti 4.2. | ||
2025 Q3 -tulosraportti 24.10.2025 | ||
2025 Q2 -tulosraportti 29.7.2025 | ||
2025 Q1 -tulosraportti 7.5.2025 |
2026 Q1 -tulosraportti
92 päivää sitten
‧34 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
2025 Q4 -tulosraportti 4.2. | ||
2025 Q3 -tulosraportti 24.10.2025 | ||
2025 Q2 -tulosraportti 29.7.2025 | ||
2025 Q1 -tulosraportti 7.5.2025 |
25,063 SEK/osake
Viimeisin osinko
0,00%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·15.7.Worst in class!Tobii has advanced strongly FUNDAMENTALLY speaking (but is robot-shorted by likely Smart Eye-associated foreign algorithm traders, as was the former subsidiary Dynavox) since the peak price of 7 kr at the end of July 2025 after the Q1 report race + good news from a price of approx. 2 kr at the beginning of May 2025. So I anticipate a new Tobii race to speculate on first, and then one can increase, for example, in Dicot Pharma in my case, perhaps with the shares instead, so that both are held, or that Tobii profit is partly transferred to a partial subscription of shares via TO-7 or similar combinations. Acquisition/agreement before a completed Phase IIb in Dicot Pharma feels quite likely - but that also depends on the price THEN, as it might eventually be cheaper with Phase III in-house, though that's a fine detail. I hope they sell the drug candidate in that case to the highest bidder... Tobii, I hope they DO NOT sell, at least in the first stage, and in fact a good bid from Dynavox of, say, 7-10 kr is OK - EVEN for Dynavox owners, assuming only new shares in Dynavox as payment. With Dynavox target prices now approx. 100 kr or more among all major banks etc., a Tobii acquisition from THEM is OK, BUT NOT if, for example, close partner Qualcomm makes a bid that could pay like 50-100 kr now :-) Or Qualcomm's competitor Texas Instrument, with whom Tobii Autosense ALSO has SCDO collaboration for generation 4 DMS at BMW, i.e., generation 3 OMS worldwide, where Autosense was first with OMS already in 2021 in BMW with Seeing Machines as a DMS supplier, while Smart Eye came up empty and completely lost BMW except in the phasing out of gen 1, which is still ongoing with one model, at least in Q1 according to Martin Krantz at Smart Eye, who has been reported by me to the EBM for other matters, i.e., insider trading and fraud regarding the concealment of BMW's DMS and OMS losses.
- 3.7.Regarding Autism Tobii secures design win for Get Set Early - delivers eyetracking for autism diagnostics 2026-02-11 The eyetracking-based screening tool for Autism Spectrum Disorder aims to enable earlier diagnosis and treatment through scientifically designed tests. Tobii, the global leader in eyetracking and pioneer in attention computing, has secured a design win for Get Set Early – a screening tool for Autism Spectrum Disorder (ASD) developed to identify early signs of autism in children as young as 12 months. The screening tool was developed by psychology professor Dr. Karen Pierce and her team at the University of California San Diego, and further developed by Butterfly Learnings. It is the first tool of its kind in India to have received CDSO certification and been approved for clinical use. Early detection crucial for effective treatment Research shows that children diagnosed with autism before the age of two exhibit better linguistic, cognitive, and social development. The brain is most malleable during the first years of life, making early detection crucial for effective treatment. Get Set Early enables early identification through a non-invasive test where the child watches a short video while the system records eye movements to measure how long the child focuses on different types of stimuli. The test generates objective biomarkers for autism spectrum disorder, making the assessment reliable and unbiased. The method is patented, scientifically validated, and based on the analysis of eye movements to detect signs of autism in children. It was developed by Dr. Karen Pierce, Associate Director of the Autism Center of Excellence at the University of California, San Diego. "Through the collaboration with Tobii, we can offer high-quality eyetracking diagnostics for early autism screening in India and global markets. This is an important step forward in our mission to make high-quality, technology-driven screening accessible to all children, everywhere. We look forward to scaling this partnership globally," says Abhishek Sen, co-founder and CEO of Butterfly Learnings. Eyetracking enabled by Tobii Eye Tracker 5L Tobii provides Butterfly Learnings with Tobii Eye Tracker 5L for integration into the Get Set Early screening tool. Tobii Eye Tracker 5L is a high-performance eyetracker developed for easy integration into digital health platforms, diagnostic tools, and other cognitive assessment products. "It is an honor for Tobii to be part of a product that can truly make a difference in people's lives. We are deeply impressed by what Butterfly Learnings has achieved with Get Set Early, where fundamental research insights have been transformed into clinical use that is approved, accessible, and scalable," says Emma Bauer, Senior Vice President, Integrations, at Tobii. The Get Set Early screening tool is now being implemented in clinics across India. In the development and integration of Tobii's eyetracking technology into the tool, Butterfly Learnings and Tobii have collaborated with Tiden Technologies, Tobii's Indian reseller specializing in research-grade neuroscience technology.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt